Department of Radiology, CHU de Besancon, 25030 Besancon, France.
Department of Radiology, CHU de Besancon, 25030 Besancon, France; Department of Radiology, Centre Leon Bérard, 69008 Lyon, France.
Diagn Interv Imaging. 2022 Sep;103(9):427-432. doi: 10.1016/j.diii.2022.04.002. Epub 2022 May 3.
The purpose of this study was to assess the long-term efficacy of CT-guided microwave ablation (MWA) in the treatment of osteoid osteoma. Secondary objectives were to assess early outcome and side-effects of MWA.
Twenty-eight consecutive patients (18 men, 10 women) with a median age of 19.5 years (IQR: 16, 25.5) with a total of 28 non-spinal osteoid osteoma treated by CT-guided MWA were retrospectively included. The ablations were performed with a median power and duration of 60 Watt and 1 min 30 s, respectively. Pain referred to osteoid osteoma was assessed at predefined time points using a 0-10 numeric rating scale. At one month, contrast-enhanced follow-up MRI was performed to evaluate the nidus vascularization and the volume of necrosis induced by MWA. Clinical success was defined by the absence of osteoid osteoma-related pain, and technical success was defined by the presence of necrosis of the nidus on the one-month post-MWA MRI.
Long term success rate was 93% (26/28) after a follow-up of 55.5 months (IQR: 25.75, 74.5) and technical success rate was 96 % (25/26). One late failure was observed after a patient had been declared cured at one month but the formal proof of a late recurrence of osteoid osteoma could not be brought. Three minor complications were reported including mild reversible superficial radial nerve injury with a skin burn (grade 2) in one patient and moderate skin burn only in two patients.
Our results suggest that CT-guided MWA is an effective option for a minimally-invasive treatment of osteoid osteoma with a low rate of complication and no late recurrence.
本研究旨在评估 CT 引导下微波消融(MWA)治疗骨样骨瘤的长期疗效。次要目的是评估 MWA 的早期结果和副作用。
回顾性纳入 28 例(男 18 例,女 10 例)连续患者,中位年龄 19.5 岁(IQR:16,25.5),共 28 例非脊柱骨样骨瘤接受 CT 引导下 MWA 治疗。消融采用中位数功率 60 瓦和中位数时间 1 分 30 秒进行。使用 0-10 数字评分量表在预定时间点评估与骨样骨瘤相关的疼痛。术后 1 个月行增强 MRI 随访,评估 MWA 引起的病灶血管化和坏死体积。临床成功定义为无骨样骨瘤相关疼痛,技术成功定义为 MWA 后 1 个月 MRI 显示病灶坏死。
28 例患者中位随访 55.5 个月(IQR:25.75,74.5),长期成功率为 93%(26/28),技术成功率为 96%(25/26)。1 例患者在 1 个月时已宣布治愈,但随后发现骨样骨瘤复发,这是唯一 1 例晚期失败病例。报告了 3 例轻微并发症,包括 1 例患者轻度可逆性浅表桡神经损伤伴皮肤灼伤(2 级)和 2 例患者中度皮肤灼伤。
我们的结果表明,CT 引导下 MWA 是治疗骨样骨瘤的一种有效微创选择,并发症发生率低,无晚期复发。